Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

254.28
+5.582.24%
Post-market: 254.280.00000.00%19:52 EDT
Volume:516.75K
Turnover:131.04M
Market Cap:16.51B
PE:17.38
High:255.85
Open:248.75
Low:248.55
Close:248.70
52wk High:265.05
52wk Low:121.40
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.04
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.44
PE(LYR):-43.54

Loading ...

Jazz Pharma director Mark Douglas Smith disposes of 1,157 shares worth $266,146.35

Reuters
·
Jun 18

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Reuters
·
Jun 17

Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Dow Jones
·
Jun 17

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

TIPRANKS
·
Jun 17

Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers

Reuters
·
Jun 17

Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration

THOMSON REUTERS
·
Jun 17

Jazz announces eleven presentations at SLEEP 2026

TIPRANKS
·
Jun 17

BRIEF-Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data At Sleep 2026, Demonstrating Real-World Impact Of Xywav

Reuters
·
Jun 17

Jazz Pharma says Phase 4 XYLO study shows cardiometabolic risk markers improve after switch to low-sodium Xywav

Reuters
·
Jun 17

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at Sleep 2026, Demonstrating Real-World Impact of Xywav® (Calcium, Magnesium, Potassium, and Sodium Oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

THOMSON REUTERS
·
Jun 17

Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jun 16

How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint

Simply Wall St.
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Dianthus Therapeutics (DNTH)

TIPRANKS
·
Jun 15

Jazz Pharma EVP, Chief Legal Officer Neena Patil disposes of 1,200 shares worth $278,196

Reuters
·
Jun 13

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Edwards Lifesciences (EW)

TIPRANKS
·
Jun 12

Jazz Pharma's Zepzelca Misses Primary Endpoint in Second-Line Lung-Cancer Trial

Dow Jones
·
Jun 12

Jazz Pharmaceuticals Shares Fall 1.7% Premarket After Co's Lung Cancer Drug Fails Late-Stage Trial

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint

TIPRANKS
·
Jun 12